[Articles] Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study

Related Posts

• [Articles] Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study

  Gedatolisib plus palbociclib and endocrine therapy showed a promising objective response rate compared with the…

• TIL-Based Combination Therapy in Metastatic Melanoma

  KEY TAKEAWAYS The TUNINTIL study phase 3 trial aimed to investigate the enhanced efficacy and…

• [Articles] Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

  TTFields therapy added to standard therapy significantly improved overall survival compared with standard therapy alone…